Has the U.S. Biotech Industry valuation changed over the past few years?

Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates. The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 7.6x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 26 May 2026	US$1.3t	US$170.0b	-US$12,285,000,013.65	16.2x	-105.1x	7.6x
Thu, 23 Apr 2026	US$1.3t	US$166.2b	-US$11,942,531,263.55	17x	-111.3x	8x
Sat, 21 Mar 2026	US$1.3t	US$169.3b	-US$15,282,661,676.77	16.7x	-83.2x	7.5x
Mon, 16 Feb 2026	US$1.3t	US$168.9b	-US$12,914,459,252.42	22.2x	-103.3x	7.9x
Wed, 14 Jan 2026	US$1.2t	US$163.5b	-US$15,154,711,813.01	20.2x	-81x	7.5x
Fri, 12 Dec 2025	US$1.2t	US$163.7b	-US$15,620,268,826.39	19.2x	-77.6x	7.4x
Sun, 09 Nov 2025	US$1.1t	US$163.6b	-US$15,721,529,627.74	17x	-71.9x	6.9x
Tue, 07 Oct 2025	US$1.1t	US$163.5b	-US$18,203,097,730.54	16.5x	-62.3x	6.9x
Thu, 04 Sep 2025	US$1.1t	US$163.5b	-US$18,341,677,831.30	15.5x	-58.6x	6.6x
Sat, 02 Aug 2025	US$1.0t	US$158.3b	-US$21,877,165,347.51	15.8x	-46.2x	6.4x
Mon, 30 Jun 2025	US$927.2b	US$156.0b	-US$23,836,878,936.09	17.2x	-38.9x	5.9x
Wed, 28 May 2025	US$911.8b	US$155.9b	-US$24,111,099,148.63	16x	-37.8x	5.8x
Fri, 25 Apr 2025	US$790.7b	US$119.2b	-US$36,562,802,211.15	20x	-21.6x	6.6x
Sun, 23 Mar 2025	US$827.4b	US$118.6b	-US$36,836,383,348.69	20.4x	-22.5x	7x
Tue, 18 Feb 2025	US$842.1b	US$116.6b	-US$36,838,458,362.91	17.6x	-22.9x	7.2x
Thu, 16 Jan 2025	US$933.0b	US$149.4b	-US$26,288,358,151.10	17x	-35.5x	6.2x
Sat, 14 Dec 2024	US$1.0t	US$150.0b	-US$26,499,023,924.94	16.6x	-37.8x	6.7x
Mon, 11 Nov 2024	US$1.1t	US$149.6b	-US$27,286,902,976.61	16.5x	-40.7x	7.4x
Wed, 09 Oct 2024	US$878.9b	US$113.1b	-US$35,894,198,277.00	20.5x	-24.5x	7.8x
Fri, 06 Sep 2024	US$891.3b	US$113.1b	-US$35,694,163,155.93	22.9x	-25x	7.9x
Sun, 04 Aug 2024	US$1.2t	US$165.8b	-US$32,803,544,510.84	25.9x	-36.7x	7.3x
Tue, 02 Jul 2024	US$1.1t	US$164.4b	-US$27,968,148,950.64	28.8x	-41.1x	7x
Thu, 30 May 2024	US$1.1t	US$164.6b	-US$26,666,955,066.31	26.8x	-41.5x	6.7x
Sat, 27 Apr 2024	US$1.1t	US$164.6b	-US$27,388,073,165.09	22.6x	-39.1x	6.5x
Mon, 25 Mar 2024	US$1.2t	US$164.3b	-US$23,931,097,513.35	21.4x	-48.6x	7.1x
Wed, 21 Feb 2024	US$1.2t	US$169.2b	-US$20,429,726,157.04	15.8x	-56.6x	6.8x
Fri, 19 Jan 2024	US$1.4t	US$204.7b	-US$22,508,448,136.00	18.3x	-63.1x	6.9x
Sun, 17 Dec 2023	US$1.4t	US$204.7b	-US$22,119,635,723.00	19.2x	-61x	6.6x
Tue, 14 Nov 2023	US$1.2t	US$204.5b	-US$21,994,312,170.00	18.6x	-54.7x	5.9x
Thu, 12 Oct 2023	US$1.3t	US$207.4b	-US$13,067,336,949.00	17.4x	-97.2x	6.1x
Sat, 09 Sep 2023	US$1.3t	US$207.5b	-US$12,633,744,533.00	17.4x	-100.7x	6.1x
Mon, 07 Aug 2023	US$1.3t	US$210.2b	-US$10,135,599,050.00	15.6x	-124.3x	6x
Wed, 05 Jul 2023	US$1.1t	US$186.2b	-US$16,059,041,068.00	13.4x	-69.8x	6x
Fri, 02 Jun 2023	US$1.1t	US$186.0b	-US$15,979,792,463.00	11.3x	-69.9x	6x


US Market	1.21%
Healthcare	3.12%
Biotech	3.07%
Biotech	3.07%

Company	Last Price	7D	1Y	Valuation
GILD Gilead Sciences	US$134.36	3.0% +US$4.8b	23.2%	PE18.1x
AMGN Amgen	US$339.30	2.6% +US$4.6b	21.4%	PE23.5x
ABBV AbbVie	US$215.70	0.9% +US$3.4b	16.1%	PE106x
IMVT Immunovant	US$34.15	29.9% +US$1.7b	139.0%	PB8.2x
ONC BeOne Medicines	US$310.25	4.5% +US$1.5b	30.2%	PE67.2x

Announcement • May 25

BioNTech SE to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE presented new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations highlighted new data for key strategic assets pumitamig and gotistobart. Four trial in progress poster presentations illustrated advancement of the Company’s ongoing pivotal trials and novel-novel combination trials, including antibody-drug conjugates. Highlights of BioNTech’s late-stage oncology programs to be presented at ASCO 2026: Pumitamig (BNT327/BMS986545) – an investigational bispecific immunomodulator combining PD-L1 checkpoint inhibition and VEGF-A neutralization, developed in collaboration with Bristol Myers Squibb Company: 1L NSCLC: Data from the interim analysis of the Phase 2 dose-optimization part of the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) showed encouraging anti-tumor activity in first-line non-small cell lung cancer. The trial evaluated pumitamig plus chemotherapy in patients with non-squamous and squamous NSCLC without actionable genomic alterations and across PD-L1 expression levels. These data mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig plus chemotherapy, adding to the reported global data in small cell lung cancer and triple-negative breast cancer. The results inform the ongoing pivotal Phase 3 part of ROSETTA Lung-02 evaluating pumitamig plus chemotherapy versus pembrolizumab plus chemotherapy. Updated data from a later cut-off date will be presented in a rapid oral presentation. Gotistobart (BNT316/ONC-392) – an investigational tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4, developed in collaboration with OncoC4 Inc.: PROC: Data from the Phase 2 PRESERVE-004 clinical trial (NCT05446298) evaluating gotistobart plus pembrolizumab in heavily pre-treated patients with platinum-resistant ovarian cancer showed durable anti-tumor activity and clinically meaningful overall survival outcomes. Together with a manageable safety profile, the results add to the growing body of evidence supporting gotistobart’s potential as a chemotherapy-free treatment option, complementing the recently announced data in second and later line squamous non-small cell lung cancer. BioNTech is advancing a diversified oncology pipeline spanning next-generation immunomodulators, ADCs, and mRNA cancer immunotherapies, both as monotherapies and novel treatment combination approaches. With more than 25 Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials, BioNTech is focused on developing innovative approaches to address the challenges of cancer treatment among the Company’s tumor focus areas from early to late-stage conditions.

Announcement • May 21

ImmunityBio Announces FDA Acceptance Of Supplemental BLA For ANKTIVA Plus BCG In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Papillary Disease

ImmunityBio, Inc. announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease without carcinoma in situ (CIS). The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 6, 2027. In the filing communication, the FDA stated, “In support of this expansion, one has submitted the results of QUILT-3.032 Cohort B and a literature-based rationale proposing that papillary NMIBC has an overlapping clinical and non-clinical profile with CIS that may allow for extrapolation of results from patients with CIS, as was demonstrated in QUILT-3.032 Cohort A, the basis of the existing indication, to those with papillary-only disease.” The Agency further provided insight as to the focus of the review of this sBLA by stating, “The scientific data detailing these overlapping features will be the focus of the review of this sBLA to determine if there is adequate justification to allow for such an extrapolation and expansion of the indication of Anktiva with BCG to include the treatment of patients with BCG-unresponsive NMIBC with papillary tumors,” while reiterating their concerns relating to single-arm trials in papillary disease alone (Cohort B) in which the initial indication for CIS and papillary disease (Cohort A) has already been approved in a single-arm trial. If approved, the sBLA would expand the current indication for ANKTIVA plus BCG and further broaden treatment options for patients with BCG-unresponsive NMIBC. The supplemental application is supported by data from the QUILT 3.032 Phase 2/3 trial (Cohort B; NCT03022825) in 80 patients with high-grade papillary-only NMIBC. As published in The Journal of Urology(Chang et al., 2025), the study met its primary endpoint with a 12-month disease-free survival (DFS) rate of 58.2% (95% confidence interval: 46.6-68.2%). The secondary endpoints of the chemo-free immunotherapy based treatment of ANKTIVA plus BCG in Cohort B that identifies the results addressing this goal of delaying progression into muscle-invasiveness and accomplishing bladder sparing are: Progression Free Survival (PFS), Cystectomy Free Survival, Disease Specific Survival (DSS). The data submitted to the Agency regarding these secondary endpoints for consideration and published in peer reviewed journals (New England Journal of Medicine and Journal of Urology), as well as accepted by NCCN with a Category 2A designation for patients treated with intravesical ANKTIVA plus BCG with BCG unresponsive non-muscle invasive bladder cancer and papillary disease alone demonstrated: Progression-Free Survival (PFS): 94.9% at 12 months and 82.0% at 36 months, indicating durable prevention of progression to muscle-invasive disease. Cystectomy Free Survival: Bladder preservation remained high, with cystectomy-free survival of 92.2% at 12 months and 83.1% at 36 months, meaning over 80% of patients avoided radical cystectomy through three years of follow-up. Disease-Specific Survival (DSS): 96.0% Disease-Specific Survival (DSS) rate at 36 months, with median DSS not yet reached at time of submission of the sBLA. The safety data submitted in this supplemental BLA was consistent with the safety data of the indication already approved, demonstrating qualitatively that the serious adverse events of ANKTIVA when combined with BCG was consistent with that of BCG alone. ANKTIVA plus BCG was previously approved by the FDA in April 2024 for the treatment of adult patients with BCG-unresponsive NMIBC with carcinoma in situ (CIS), with or without papillary tumors. Non-muscle-invasive bladder cancer (NMIBC) represents approximately 80% of all bladder cancer diagnoses in the United States, approximately 85% of people diagnosed with NMIBC in the U.S. each year present with papillary disease. Patients with papillary disease who become unresponsive to BCG therapy face a high risk of recurrence and progression and often have limited bladder-sparing treatment options available. The interleukin-15 (IL-15) cytokine plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

U.S. Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Amgen Sets CFO Succession With Thomas Dittrich Returning and US$12.5m Incentive Package

Natera Launches Enhanced Panorama Nipt Powered by Snp-Informed Deep Sequencing Technology

President & CEO of Immunovant notifies of intention to sell stock

AbbVie Lifts 2026 Outlook as Immunology and Neuroscience Drive Growth Over Humira Challenges

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential

BioNTech SE to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

ONC: Hematology Franchise And Upcoming Trial Readouts Will Support Future Upside

Gilead Expands Oncology Portfolio With Tubulis Acquisition and Raises Full-Year Revenue Outlook

ADMA Biologics Faces Multiple Investigations and Guidance Cut After Sharp Stock Drop and ASCENIV Gains

Consensus revenue estimates increase by 28%, EPS downgraded

ImmunityBio Announces FDA Acceptance Of Supplemental BLA For ANKTIVA Plus BCG In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Papillary Disease

Insmed Sees BRINSUPRI Surge and Pipeline Progress With Q1 Revenue at $306 Million

PTCT: Early Neurology Execution Will Drive Huntington Progress Toward Bullish 2026 Outlook

BCRX: Astria Integration And Licensing Deal Will Support Hereditary Angioedema Expansion

New major risk - Financial position

Vaxcyte Completes Phase 3 Enrollment for VAX-31 and Plans Phase 1 Launch for VAX-A1